Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 211

Sort by

Sort Order Select

Journal Articles

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy

Blood (2025) 145 (8): 823–839.

https://doi.org/10.1182/blood.2024025366

Published: 2025

Includes: Supplemental data

Journal Articles

Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) and Secondary Central Nervous System (sCNS) Involvement from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Sairah Ahmed, Avyakta Kallam, Matthew Frigault, Bradley D. Hunter, Sagar S. Patel, David Bernasconi, Soyoung Kim, Tracy Krimmel, Fei Fei Liu, Debasmita Roy, Marcelo C. Pasquini, Jennifer L. Crombie

Blood (2024) 144 (Supplement 1): 472.

https://doi.org/10.1182/blood-2024-199702

Published: 2024

Journal Articles

Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Blood (2024) 144 (Supplement 1): 470.

https://doi.org/10.1182/blood-2024-199723

Published: 2024

Journal Articles

Radiation Therapy and Monocyte Activation in Large B-Cell Lymphoma Patients Treated with CAR T-Cell Therapy

Blood (2024) 144 (Supplement 1): 4377.

https://doi.org/10.1182/blood-2024-203844

Published: 2024

Journal Articles

Imaging Activated Innate Immune Myeloid Cells in Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Following CAR T-Cell Therapy

Ajlan Al Zaki, Margie Sutton, Abdur Rehman, Cao Cuong Le, Seth Gammon, Arianna Napoli, Ping Yang, Neeraj Y. Saini, Sairah Ahmed, Ghayas C. Issa, Partow Kebriaei, Michael Davies, Elizabeth J. Shpall, Jeena Varghese, Lesley Flynt, Sattva S. Neelapu, David Piwnica-Worms

Blood (2024) 144 (Supplement 1): 3428.

https://doi.org/10.1182/blood-2024-211204

Published: 2024

Journal Articles

Peripheral Blood CAR T-Cell Level Using a Clia-Validated Assay Is Prognostic for Treatment Response and Icans in Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3001.

https://doi.org/10.1182/blood-2024-208300

Published: 2024

Journal Articles

Evaluation of Outcomes and Toxicities of Commercial Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Real-World Evidence (RWE) from 10 US Academic Centers

Blood (2024) 144 (Supplement 1): 2377.

https://doi.org/10.1182/blood-2024-203753

Published: 2024

Journal Articles

Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report

Jiasheng Wang, Shakthi Bhaskar, Babatunde Adedokun, Olalekan O. Oluwole, Leland Metheny, Amy Moskop, Caron A. Jacobson, Geoffrey Shouse, Sairah Ahmed, Armin Ghobadi, Saurabh Dahiya, Jiali Yan, Zhen-Huan Hu, Timothy Best, Jenny J. Kim, Debbie L. Mirjah, Marcelo C. Pasquini, Frederick L. Locke

Blood (2024) 144 (Supplement 1): 527.

https://doi.org/10.1182/blood-2024-209093

Published: 2024

Journal Articles

Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Blood (2024) 144 (Supplement 1): 526.

https://doi.org/10.1182/blood-2024-199139

Published: 2024

Journal Articles

Risk Analysis of Cytokine Release Syndrome, Immune Effector Cell- Associated Neurotoxicity Syndrome, and Immune Effector Cell- Associated Hemophagocytic Lymphohistiocytosis-like Syndrome in BiTE Therapy Vs CAR-T Therapy Using Real World Data

Alexandra Elias, Rishab Prakash, Ranjit Nair, Luis Malpica, Hun Ju Lee, Eguono Maples, Samantha Carlson, Luis E. Fayad, Krina K. Patel, Sairah Ahmed, Swaminathan P Iyer

Blood (2024) 144 (Supplement 1): 611.

https://doi.org/10.1182/blood-2024-212332

Published: 2024

Journal Articles

Real World Comparison of Efficacy and Safety of Fludarabine-Versus Bendamustine-Based Lymphodepleting Chemotherapy for CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Relapse/Refractory (r/r) Large B-Cell Lymphoma (LBCL)

Alaa Ali, Nausheen Ahmed, Soyoung Kim, Matthew Bye, Sayeef Mirza, Alex Gordon Sieg, Christopher Strouse, Kalyan Nadiminti, Priyanka A. Pophali, Rammurti T. Kamble, Lohith Gowda, Cameron J. Turtle, Christine L. Phillips, Marcelo C. Pasquini, Sairah Ahmed, Siddhartha Ganguly, Amy Moskop

Blood (2024) 144 (Supplement 1): 71.

https://doi.org/10.1182/blood-2024-200269

Published: 2024

Journal Articles

Retreatment with R-CHOP-like Therapy Is Active with Durable Responses in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma

Eduardo Edelman Saul, Bryan Valcarcel, Amy A. Ayers, Mansoor Noorani, Dai Chihara, Fateeha Furqan, Sairah Ahmed, Swaminathan P Iyer, Sattva S. Neelapu, Luis E. Fayad, F. B. Hagemeister, Chijioke Nze, Preetesh Jain, Michael Wang, Paolo Strati, Ayushi Chauhan, Francisco Vega, Christopher R. Flowers, Jason R. Westin

Blood (2024) 144 (Supplement 1): 4454.

https://doi.org/10.1182/blood-2024-211247

Published: 2024

Journal Articles

Occurrence and Predictors of Patient Reported Fertility Discussions in Non-Hodgkin Lymphoma Patients: Utilizing the Lymphoma Epidemiology of Outcomes (LEO) Cohort Study

Blood (2024) 144 (Supplement 1): 3736.

https://doi.org/10.1182/blood-2024-211091

Published: 2024

Journal Articles

Developing a Fit-for-Purpose Composite Symptom Score for Representing Symptom Burden for Managing CRS and Icans after CAR T-Cell Therapy

Xin Shelley Wang, Samer A. Srour, Sattva S. Neelapu, Shu-En Shen, Laila Noor, Sairah Ahmed, Elizabeth J. Shpall

Blood (2024) 144 (Supplement 1): 2282.

https://doi.org/10.1182/blood-2024-210494

Published: 2024

Journal Articles

Long-Term Follow-up of Crenolanib Maintenance after Allogeneic Transplantation in Newly Diagnosed and Relapsed FLT3 Mutated AML

Betul Oran, David Marin, Qaiser Bashir, Sairah Ahmed, Amanda L. Olson, Uday Popat, Partow Kebriaei, Elizabeth J. Shpall, Vinay Jain, Richard E. Champlin

Blood (2024) 144 (Supplement 1): 1497.

https://doi.org/10.1182/blood-2024-207763

Published: 2024

Journal Articles

Brentuximab Associated Guillain-Barré Syndrome (BV-GBS): Case Series and a Review of Pharmacovigilance FDA Adverse Reporting System (FAERS)

Roshini Pradeep, Zeynep Nazli Benekli, Ranjit Nair, Luis Malpica, Hun Ju Lee, Eguono Maples, Samantha Carlson, Luis E. Fayad, Sairah Ahmed, Swami P. Iyer

Blood (2024) 144 (Supplement 1): 7776.

https://doi.org/10.1182/blood-2024-202119

Published: 2024

Journal Articles

Neighborhood-Level Social Determinants of Health and Cardiovascular Burden in Adolescent and Young Adult Patients Treated for Hodgkin Lymphoma

Elizabeth Rodriguez, Nader Kim El-Mallawany, Sairah Ahmed, Branko Cuglievan, John Andrew Livingston, Christopher R. Flowers, Qian Xiao, Michael E. Roth, Michelle A.T. Hildebrandt

Blood (2024) 144 (Supplement 1): 6359.

https://doi.org/10.1182/blood-2024-208944

Published: 2024

Journal Articles

Concomitant Use of Antibiotics During Immune Checkpoint Inhibitor (CPI)-Based Salvage Therapy Does Not Impact Post-ASCT Outcomes in Patients with Relapsed/Refractory Hodgkin Lymphoma (RRHL)

Blood (2024) 144 (Supplement 1): 4425.

https://doi.org/10.1182/blood-2024-197923

Published: 2024

Journal Articles

NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Sairah Ahmed, John F. DiPersio, James H Essell, Catherine S. Diefenbach, Miguel Angel Perales, Cristina Castilla-Llorente, Saurabh Dahiya, Sohail Chaudhry, Heng Xu, Yi Liu, Christie Fanton, Zachary Lee, Mario Q. Marcondes, Mary Tagliaferri, Jonathan Zalevsky, David B. Miklos, Cameron J. Turtle, Joseph P. McGuirk

Blood (2024) 144 (Supplement 1): 2068.

https://doi.org/10.1182/blood-2024-203576

Published: 2024

Journal Articles

Improving Outcomes in Plasmablastic Lymphoma: A Multicenter Experience from an American Cohort

Blood (2024) 144 (Supplement 1): 573.

https://doi.org/10.1182/blood-2024-198008

Published: 2024

NARROW

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy

Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) and Secondary Central Nervous System (sCNS) Involvement from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Radiation Therapy and Monocyte Activation in Large B-Cell Lymphoma Patients Treated with CAR T-Cell Therapy

Imaging Activated Innate Immune Myeloid Cells in Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Following CAR T-Cell Therapy

Peripheral Blood CAR T-Cell Level Using a Clia-Validated Assay Is Prognostic for Treatment Response and Icans in Large B-Cell Lymphoma

Evaluation of Outcomes and Toxicities of Commercial Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Real-World Evidence (RWE) from 10 US Academic Centers

Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report

Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Risk Analysis of Cytokine Release Syndrome, Immune Effector Cell- Associated Neurotoxicity Syndrome, and Immune Effector Cell- Associated Hemophagocytic Lymphohistiocytosis-like Syndrome in BiTE Therapy Vs CAR-T Therapy Using Real World Data

Real World Comparison of Efficacy and Safety of Fludarabine-Versus Bendamustine-Based Lymphodepleting Chemotherapy for CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Relapse/Refractory (r/r) Large B-Cell Lymphoma (LBCL)

Retreatment with R-CHOP-like Therapy Is Active with Durable Responses in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma

Occurrence and Predictors of Patient Reported Fertility Discussions in Non-Hodgkin Lymphoma Patients: Utilizing the Lymphoma Epidemiology of Outcomes (LEO) Cohort Study

Developing a Fit-for-Purpose Composite Symptom Score for Representing Symptom Burden for Managing CRS and Icans after CAR T-Cell Therapy

Long-Term Follow-up of Crenolanib Maintenance after Allogeneic Transplantation in Newly Diagnosed and Relapsed FLT3 Mutated AML

Brentuximab Associated Guillain-Barré Syndrome (BV-GBS): Case Series and a Review of Pharmacovigilance FDA Adverse Reporting System (FAERS)

Neighborhood-Level Social Determinants of Health and Cardiovascular Burden in Adolescent and Young Adult Patients Treated for Hodgkin Lymphoma

Concomitant Use of Antibiotics During Immune Checkpoint Inhibitor (CPI)-Based Salvage Therapy Does Not Impact Post-ASCT Outcomes in Patients with Relapsed/Refractory Hodgkin Lymphoma (RRHL)

NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Improving Outcomes in Plasmablastic Lymphoma: A Multicenter Experience from an American Cohort

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only